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Abstract
Background: In response to increases in methamphatemine-associated sexually transmitted diseases, the San Francisco
Department of Public Health implemented a contingency management (CM) field program called the Positive
Reinforcement Opportunity Project (PROP).
Methods: Methamphetamine-using men who have sex with men (MSM) in San Francisco qualified for PROP following
expressed interest in the program, provision of an observed urine sample that tested positive for methamphetamine
metabolites and self-report of recent methamphetamine use. For 12 weeks, PROP participants provided observed urine
samples on Mondays, Wednesdays and Fridays and received vouchers of increasing value for each consecutive sample
that tested negative to metabolites of methamphetamine. Vouchers were exchanged for goods and services that
promoted a healthy lifestyle. No cash was provided. Primary outcomes included acceptability (number of enrollments/
time), impact (clinical response to treatment and cost-effectiveness as cost per patient treated).
Results: Enrollment in PROP was brisk indicating its acceptability. During the first 10 months of operation, 143 men
sought treatment and of these 77.6% were HIV-infected. Of those screened, 111 began CM treatment and averaged 15
(42%) methamphetamine-free urine samples out of a possible 36 samples during the 12-week treatment period; 60%
completed 4 weeks of treatment; 48% 8 weeks and 30% 12 weeks. Across all participants, an average of $159 (SD =
$165) in vouchers or 35.1% of the maximum possible ($453) was provided for these participants. The average cost per
participant of the 143 treated was $800.
Conclusion: Clinical responses to CM in PROP were similar to CM delivered in drug treatment programs, supporting
the adaptability and effectiveness of CM to non-traditional drug treatment settings. Costs were reasonable and less than
or comparable to other methamphetamine outpatient treatment programs. Further expansion of programs like PROP
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could address the increasing need for acceptable, feasible and cost-effective methamphetamine treatment in this group
with exceptionally high rates of HIV-infection.
Background
Methamphetamine abuse is increasingly one of the most
serious public health problems in the United States.
Among men who have sex with men (MSM), including
both gay and bisexual men, methamphetamine is a popu-
lar street drug [1,2], especially along the West Coast. Prev-
alence rates for methamphetamine use in the previous 6
months among MSM in San Francisco range between
11%–17% [3]. This level of drug use causes concern
among public health professionals because of the obvious
problems of escalating abuse and dependence. Even more
troubling is the fact that methamphetamine use is
strongly associated with increased sexual risk behaviors
and sexually transmitted diseases (STDs) and HIV-trans-
mission in MSM [4-6]. Interventions that reduce or elimi-
nate methamphetamine use for MSM in drug treatment
settings show corresponding and concomitant reductions
in sexual risk behaviors that increase STD/HIV transmis-
sion and, as such, may represent an important component
of a comprehensive STD/HIV control strategy for MSM
[7].
A promising intervention for producing at least short-term
reductions in methamphetamine use is contingency man-
agement. Contingency management (CM) is an effica-
cious behavioral therapy that provides immediate positive
reinforcement – cash incentives or cash equivalents – in
exchange for biological evidence of drug abstinence [8,9].
The treatment program can be implemented by staff with
minimal clinical training and by itself can produce signif-
icant short-term reductions in methamphetamine use in
treatment-seeking methamphetamine-dependent men
[7]. This article describes the implementation and brief
evaluation of a CM treatment program in response to
increases in methamphetamine-associated STDs includ-
ing HIV infections by the San Francisco Department of
Public Health.
Methods
Participants
In the fall of 2004 the San Francisco Public Health Depart-
ment fielded a program of contingency management for
methamphetamine-using MSM in order to decrease meth-
amphetamine-associated sexual risk behaviors leading to
the spread of STDs and HIV infection. The Positive Rein-
forcement Opportunity Project (PROP, [10]) was started
in three health services settings: San Francisco General
Hospital out-patient AIDS Ward, Continuum HIV Day
Services, and MAGNET, a full-service STD/HIV prevention
organization focused on gay men's sexual health. Public
Health Department staff in the STD Prevention and Con-
trol Section managed the program. That staff included a
program coordinator and a health worker. Neither had
professional experience in substance use treatment.
PROP was promoted by word of mouth and flyers distrib-
uted to medical providers serving MSM at risk for meth-
amphetamine abuse. Eligible participants were
methamphetamine-using MSM seeking to reduce or elim-
inate their use of the drug. To enroll in PROP, metham-
phetamine-using MSM visited one of the sites and staff
screened potential participants to determine recent meth-
amphetamine use (any use in the past 7 days or signed
referral from a physician documenting current metham-
phetamine dependence). Those who met the initial eligi-
bility criteria met with a health worker to receive a 15-
minute orientation to PROP, to complete brief admission
forms describing their drug use, sexual behaviors, and
infectious disease history, and to provide a pre-baseline
urine sample tested for metabolites of methamphetamine
using a radioimmunoassay (MedTox, Phamatech, San
Diego, California). Participants were required to have a
positive pre-baseline urine test or medical documentation
of current methamphetamine dependence to initiate
treatment. Methamphetamine-using MSM unable to doc-
ument current methamphetamine dependence (either
with a positive pre-baseline urine test or physician's refer-
ral) were not enrolled in PROP.
Intervention
Enrolled participants met with a health worker on M-W-F
between 8–10 am to provide a directly observed urine
sample. Participants were awarded vouchers (i.e., credits)
that were redeemable for goods or services that promoted
a healthy drug-free lifestyle in exchange for urine samples
that were free of metabolites of methamphetamine. The
reward schedule is shown in Table 1. A rapid reset proce-
dure allowed participants to return to their place in the
escalating schedule after producing three consecutive
urine samples that were negative for methamphetamine.
At no time was cash provided to participants. When par-
ticipants chose to redeem their vouchers, staff purchased
selected items through the Internet or on the telephone
using a credit card. Items were received by mail or made
available to the participant for pick-up.
Measures
Participant characteristics were assessed using a brief base-
line survey of recent drug use and sexual risk behaviors.
Methamphetamine abstinence was assessed using theBMC Public Health 2006, 6:214 http://www.biomedcentral.com/1471-2458/6/214
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urine samples analyzed for the presence of methamphet-
amine metabolites. Methamphetamine-positive urines
and missed appointments were counted as failures. Meas-
ures, including the level of cash vouchers accrued, were
managed with a computer program specifically created for
the project. Costs for implementing PROP were calculated
as the total spent on rewards, urine specimen collection
and test kits, facility space rental, promotion and the staff
time.
While the UCLA Human Subjects Protection Committee
provided oversight of the evaluation activities for this
public health program, the program itself was non-
research and written informed consent was not obtained
from participants.
Results
By the end of the first 10 months of operation (October
2004 to July 2005), 143 unduplicated MSM were eligible
and enrolled in the program (14.3 participants per
month). As seen in Table 2, participants in the program
reported extensive experience with methamphetamine
use, with the vast majority reporting at least weekly meth-
amphetamine use. High rates of injection drug use were
noted as well as high rates of sexual risk behavior and
prior STDs.
Of those 143 who enrolled in PROP, 111 returned for
their initial visit and began the CM treatment program. A
total of 32 individuals were ineligible for PROP either due
to inability to document current methamphetamine
dependence or to failure to return to clinic. On average (+/
-S.D.) PROP participants produced 15 (+/-13.5) metham-
phetamine metabolite-free urine samples of the possible
36 samples over the 12-week treatment period. Fifty-seven
(52%) achieved 12 metabolite-free urine samples; an
additional 19 (17%) were able to provide 24 metabolite-
free samples, with only 9 (8.1%) providing all 36 samples
Table 1: Schedule of incentives for the contingency management program used in PROP
Monday Wednesday Friday Bonus Weekly totals
Week 1 $2.50 $3.75 $5.00 $10.00 $21.25
Week 2 $6.25 $7.50 $8.75 $10.00 $32.50
Week 3 $10.00 $10.00 $10.00 $10.00 $40.00
Week 4 $10.00 $10.00 $10.00 $10.00 $40.00
Week 5 $10.00 $10.00 $10.00 $10.00 $40.00
Week 6 $10.00 $10.00 $10.00 $10.00 $40.00
Week 7 $10.00 $10.00 $10.00 $10.00 $40.00
Week 8 $10.00 $10.00 $10.00 $10.00 $40.00
Week 9 $10.00 $10.00 $10.00 $10.00 $40.00
Week 10 $10.00 $10.00 $10.00 $10.00 $40.00
Week 11 $10.00 $10.00 $10.00 $10.00 $40.00
Week 12 $10.00 $10.00 $10.00 $10.00 $40.00
Grand total $453.75
Table 2: Drug use, sexual behavior, and sexually transmitted 
disease history in methamphetamine-using men who have sex 
with men at entry in the Positive Reinforcement Opportunity 
Project, San Francisco, 2004–2005.
N = 143 Percent(n)
Drug use responses
Methamphetamine use
Daily 42.7% (61)
Weekly 43.4% (62)
Monthly or less 13.9% (20)
Years prior methamphetamine use
0 to 2 years 17.5% (25)
3 to 5 years 25.9% (37)
6 to 10 years 18.9% (27)
More than 10 years 37.8% (54)
Route of administration1
Smoke 69.9% (100)
Intranasal 67.1% (96)
Inject 54.5% (78)
Rectal 40.6% (58)
Sexual behavior responses
Use of methamphetamine with sex
Yes 88.1% (126)
No 11.2% (16)
Sexual partners, past month
None 18.2% (26)
1–2 40.6% (58)
3–5 18.9% (27)
6 or more 22.4% (32)
Sexual behaviors, past month1
Unprotected insertive anal sex 70.6% (101)
Unprotected receptive anal sex 67.8% (97)
Unprotected insertive vaginal sex 16.1% (23)
Sexually transmitted disease history
Syphilis, past year 20.3% (29)
Gonorrhea, past month 32.9% (47)
Chlamydia, past month 15.4% (22)
HIV status
Positive 77.6% (111)
Negative 21.7% (31)
1 Participants could endorse more than one response to this item.BMC Public Health 2006, 6:214 http://www.biomedcentral.com/1471-2458/6/214
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free of drug metabolite. Sixty-percent completed 4 weeks
of treatment; 48%, 8 weeks and 30%, 12 weeks. The aver-
age (+/-S.D.) payout per participant for "reinforcing"
methamphetamine free urine samples was $159 (+/-
$165) or 35.1% of the possible $453.
The sum of other program costs divided by the number of
enrollees was $800.
Discussion
We successfully implemented a methamphetamine treat-
ment program for methamphetamine-dependent men
using CM. Participant characteristics and abstinence out-
comes were comparable to MSM who received CM as part
of a treatment research program [7]. The 30% retention
rate for PROP at the end of 12 weeks is lower than that in
studies of CM among methamphetamine-dependent
MSM [7] and methamphetamine-dependent heterosexu-
als [11]. One reason may be that outcomes using CM are
sensitive to the richness of the reinforcement schedule
[12] and participants in PROP could earn approximately
one-third possible in the other CM reports. Despite differ-
ences in retention, the average earning per participant in
PROP (35.1% of the maximum) is close to that reported
in treatment research on the use of CM with methamphet-
amine-dependent MSM (32.4% of the maximum) [7].
CM was popular among the target community and readily
delivered by health department staff with limited training
in substance abuse treatment. In San Francisco, metham-
phetamine-using MSM were willing to comply with the
requirement for thrice-weekly observed urine collection
in order to reduce their methamphetamine use. Our pre-
liminary findings suggest that the contingency manage-
ment approach is a feasible and cost-effective means to
reduce methamphetamine use in community settings.
The feasibility of PROP is further suggested by the strong
participation in the program. One concern is that indigent
individuals who do not use methamphetamine may try to
"scam" the program in order to access financial benefit.
The low rates of complete abstinence in this project do not
support that concern. PROP participants report long his-
tories of methamphetamine use with current use indi-
cated by a positive urine drug screen at admission or
medical documentation. Further, PROP participants
responded to the CM at similar rates in producing metab-
olite-free urine samples as did treatment-seeking metham-
phetamine-dependent MSM [7]. If methamphetamine-
naïve PROP participants did try to deceptively enter into
the program, results indicate they were unable to do it
consistently.
The costs of implementing PROP were reasonable. In this
community-based program, fixed costs included the con-
tingencies ($17,649), a one-time rent payment ($25,000)
and urine test kit costs ($6,700). Staffing required one
full-time study coordinator and a part-time assistant tota-
ling $65,000 yearly. The total allocated for this program
was $114,349 or a per-capita cost of $800 for the 143 par-
ticipants who enrolled in PROP. Costs incurred by public
health agencies implementing CM for addressing meth-
amphetamine use among MSM could be lessened by con-
tributions from communities and alternative funding
agencies.
This report evaluates PROP as a real-world public health
program and not a research project, an approach that pre-
cluded linking personally identifying information with
responses to the intervention, yielding only group-level
responses. These are initial outcomes, as only during-
treatment data were available, which limits any under-
standing of the sustained effects of the CM treatment.
Conclusion
These findings provide valuable information useful in
planning community-based interventions for metham-
phetamine users. This report recounts one of the first
adaptations of the CM intervention used outside of spe-
cific research or drug-treatment settings. The program was
successful in helping methamphetamine-using MSM, a
group with an extraordinarily high prevalence of HIV at
baseline, to reduce their drug use. The evaluation high-
lights the flexibility and potency of CM when adapted to
address a methamphetamine use problem closely linked
to HIV transmission via sexual and drug-related behaviors
(injection use) in an urban community of MSM. To the
extent that CM reduces episodes of methamphetamine
use and concomitant risky sexual behaviors, significant
improvements may accrue as indicated by more organized
lives for participants and by fewer potential transmission
risk events within a community experiencing conjoined
methamphetamine and HIV epidemics. Costs for imple-
menting this CM program are modest and within ranges
worth considering when selecting interventions to address
drug-associated STD and HIV transmission in the context
of a comprehensive prevention strategy. PROP continues
to be implemented by the San Francisco Public Health
Department and wider availability of CM may provide for
the necessary expansion in treatment required to address
the burgeoning methamphetamine epidemic in groups of
users at high risk for HIV transmission.
There are limitations to this report. The most important of
these is that no comparison condition was included,
which precludes statements of causality. It is possible that
some or all of the outcomes were due to factors that arise
in delivering PROP. As well, PROP implemented CM as a
clinical program, and as such, the evaluation lacks the
rigor and control (e.g., experimental design, psychometri-Publish with BioMed Central    and   every 
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cally sound measures) common to clinical trials of behav-
ioral therapies. Still the research literature is replete with
information on the efficacy of CM for reducing stimulant
use. The challenge to the fields of research and public
health practice now involves finding ways to adapt and to
use this efficacious behavioral intervention to reduce drug
use and associated HIV-related transmission behaviors in
communities facing these interwoven public health prob-
lems.
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